Drug Type Bispecific antibody |
Synonyms + [1] |
Target |
Mechanism CALR inhibitors(calreticulin inhibitors), CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Myelofibrosis | Phase 1 | CA | 20 Dec 2023 | |
Myelofibrosis | Phase 1 | US | 20 Dec 2023 | |
Myelofibrosis | Phase 1 | FR | 20 Dec 2023 | |
Thrombocythemia, Essential | Phase 1 | FR | 20 Dec 2023 | |
Thrombocythemia, Essential | Phase 1 | GB | 20 Dec 2023 | |
Thrombocythemia, Essential | Phase 1 | DE | 20 Dec 2023 | |
Thrombocythemia, Essential | Phase 1 | US | 20 Dec 2023 | |
Thrombocythemia, Essential | Phase 1 | ES | 20 Dec 2023 | |
Thrombocythemia, Essential | Phase 1 | CA | 20 Dec 2023 | |
Hematologic Neoplasms | Phase 1 | US | - |